Cancer Cachexia Market Report 2026

Cancer Cachexia Market Overview

• Cancer Cachexia market size has reached to $2.6 billion in 2025 • Expected to grow to $3.35 billion in 2030 at a compound annual growth rate (CAGR) of 5.1% • Growth Driver: Impact Of Cancer Prevalence On The Cancer Cachexia Market • Market Trend: Innovative Treatments In The Cancer Cachexia Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Cancer Cachexia Market?

Cancer cachexia is a complex metabolic syndrome characterized by progressive weight loss, muscle wasting, weakness, fatigue, and loss of appetite in individuals with cancer. It is a multifactorial condition resulting from a combination of factors such as inflammation, metabolic abnormalities, and the presence of tumors. Cancer cachexia can significantly impact a patient's quality of life, impairing their ability to tolerate cancer treatments and reducing their overall survival. The main therapeutics for cancer cachexia are progestogens, corticosteroids, combination therapies, and others. Progestogens are a type of medication often used in cancer cachexia treatment. They work by mimicking the effects of natural progesterone hormones in the body, potentially helping to increase appetite and muscle mass in patients. Various mechanisms of action include appetite stimulators, weight loss stabilizers, and others, and are distributed through hospital stores, retail pharmacy stores, and online pharmacies.

What Is The Cancer Cachexia Market Growth Forecast?

The cancer cachexia market size is expected to see strong growth in the next few years. It will grow to $3.35 billion in 2030 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to increasing demand for personalized cachexia treatments, rising clinical research into novel mechanisms, expansion of outpatient oncology services, growing use of digital patient monitoring tools, increasing focus on quality-of-life outcomes. Major trends in the forecast period include increasing use of combination drug regimens, rising focus on muscle preservation therapies, growing adoption of nutritional supplementation strategies, expansion of anti-inflammatory cachexia treatments, enhanced monitoring of cachexia progression.

What Is The Driver Of The Cancer Cachexia Market?

The increasing prevalence of cancer is expected to propel the growth of the cancer cachexia market going forward. Cancer refers to a condition where abnormal cells proliferate uncontrollably in the body, forming tumors and disrupting normal bodily processes. The cases of cancer is attributed to various factors, including lifestyle changes, environmental factors, an aging population, genetic predisposition, improved diagnostic methods leading to earlier detection, and increased awareness, prompting more people to seek medical attention. Advancements in medical technology and a greater understanding of cancer and its complications are resulting in more frequent diagnoses and reporting of cancer cachexia. Healthcare professionals are improving their ability to identify cachexia symptoms, facilitating earlier interventions and treatment commencement. For instance, in July 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, In 2023, an estimated 165,000 Australians were newly diagnosed with cancer, which equates to over 450 cases each day, and males represented about 55% of these diagnoses. Therefore, the increasing prevalence of cancer is driving the growth of the cancer cachexia industry.

Key Players In The Global Cancer Cachexia Market

Major companies operating in the cancer cachexia market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca plc, Novartis International AG, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Kyowa Kirin Co. Ltd., Hikma Pharmaceuticals plc, Endo International plc, Aspen Pharmacare Holdings Limited, Lupin Limited, Mallinckrodt plc, Akorn Inc., Aeterna Zentaris, XBiotech Inc.

Global Cancer Cachexia Market Trends and Insights

Major companies operating in the cancer cachexia market are developing innovative medications, such as monoclonal antibodies for cachexia, to develop a targeted treatment for cancer cachexia, aiming to improve body weight, muscle mass, and overall quality of life for affected patients. A monoclonal antibody for cachexia targets and inhibits factors causing muscle and weight loss. For instance, in September 2024, Pfizer Inc., a US-based pharmaceutical company, announced the positive results of its Phase 2 study for Ponsegromab, a monoclonal antibody targeting GDF-15, in patients with cancer cachexia. The study demonstrated a significant increase in body weight and improvements in muscle mass, appetite, and physical activity, with the 400 mg dose showing the most robust results. Based on these promising findings, Pfizer plans to initiate registration-enabling studies in 2025 to further investigate Ponsegromab’s potential for treating cancer cachexia.

What Are Latest Mergers And Acquisitions In The Cancer Cachexia Market?

In January 2023, LG Chem Ltd., a South Korea-based chemical company, acquired AVEO Oncology for an undisclosed amount. Through this acquisition, LG Chem aims to diversify its product portfolio and enhance its capabilities in drug development, commercialization, and acquisitions, ultimately accelerating its progress toward delivering cutting-edge cancer treatments. AVEO Oncology is a US-based biopharmaceutical company that provides a potential treatment for cancer cachexia.

What Defines the Cancer Cachexia Market?

The cancer cachexia market consists of revenues earned by entities by providing services such as nutritional counseling, physical therapy, and exercise training. The market value includes the value of related goods sold by the service provider or included within the service offering. The cancer cachexia market also includes sales of anabolic steroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and oral nutritional supplements. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Cancer Cachexia Market Report 2026?

The cancer cachexia market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the cancer cachexia industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.